Upstream Bio Finalizes Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
UPB is trading near its 52-week low of $5.85 (15% above the low).
Summary
Upstream Bio announced finalized Phase 3 development plans for verekitug in severe asthma and CRSwNP following FDA End-of-Phase 2 meetings. The company will run one placebo-controlled trial in each indication, evaluating a 400mg dose every 12 weeks in broad patient populations, with a total of approximately 1,500 patients. Primary endpoints are annualized asthma exacerbation rates over 48 weeks for asthma, and co-primary nasal polyp score and nasal congestion score at 48 weeks for CRSwNP. This follows positive Phase 2 data and provides a clear path to potential BLA submission and launch as early as 2030. The announcement de-risks the clinical program and sets a concrete timeline for late-stage development.
At the time of this announcement, UPB was trading at $6.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $362.6M. The 52-week trading range was $5.85 to $33.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.